Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

P2X7 in Cancer: From Molecular Mechanisms to Therapeutics

Open access
Lara, Romain, Adinolfi, Elena, Harwood, Catherine A., Philpott, Mike, Barden, Julian A., Di Virgilio, Francesco, McNulty, Shaun · 2020 · Frontiers in Pharmacology

Abstract

P2X7 is a transmembrane receptor expressed in multiple cell types including neurons, dendritic cells, macrophages, monocytes, B and T cells where it can drive a wide range of physiological responses from pain transduction to immune response. Upon activation by its main ligand, extracellular ATP, P2X7 can form a non-selective channel for cations to enter the cell. Prolonged activation of P2X7, via high levels of extracellular ATP over an extended time period can lead to the formation of a macropore, depolarisation of the plasma membrane and ultimately to cell death. Thus, dependent on its activation state, P2X7 can either drive cell survival and proliferation, or induce cell death. In cancer, P2X7 has recently been shown to have a broad range of functions, including playing key roles in the development and spread of tumour cells. It is therefore unsurprising that P2X7 has been reported to be up-regulated in several malignancies. Critically, ATP is present at high extracellular concentrations in the tumour microenvironment (TME) compared with levels observed in normal tissues. These high levels of ATP should present a survival challenge for cancer cells, potentially leading to constitutive receptor activation, prolonged pore formation and ultimately to cell death. Therefore, to deliver the proven advantages for P2X7 in driving tumour survival and metastatic potential, the P2X7 macropore must be tightly controlled whilst retaining other functions. Studies have shown that commonly expressed P2X7 splice variants, distinct SNPs and post-translational receptor modifications can impair the capacity of P2X7 to open the macropore. These receptor modifications and potentially others may ultimately protect cancer cells from the negative consequences associated with constitutive activation of P2X7. Significantly, the effects of both P2X7 agonists and antagonists in preclinical tumour models of cancer demonstrate the potential for agents modifying P2X7 function, to provide innovative cancer therapies. This review summarises recent advances in understanding of the structure and functions of P2X7 and how these impact P2X7 roles in cancer progression. We also review potential therapeutic approaches directed against the receptor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.00793

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 169

Metadata

Authors
Lara, R., Adinolfi, E., Harwood, C. A., Philpott, M., Barden, J. A., Di Virgilio, F., & McNulty, S.
Venue
Frontiers in Pharmacology
Published
2020-06-04
Volume
11
Pages
793-793
ISSN
1663-9812 (ISSN-L)
OpenAlex
W3032938756
Cited by
169
References
35
FWCI
13.34
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.